Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 409306 versus placebo in Alzheimer's disease
2013-005031-24Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of osoresnontrine in Alzheimer's disease (AD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Neuropsychological Test Battery response. Started Nov 2014; status: completed.
02
Drugs
osoresnontrine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2013-005031-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005031-24.